ECCMID 2020 is approaching: don’t miss the opportunity to enjoy Prof. Brigitte Autran’s Keynote Lecture. Register now!

We are extremely pleased to have Prof. Autran (Emeritus Professor of Immunology at Sorbonne-Université Faculty of Medicine) as a keynote speaker at ECCMID 2020! The title of her lecture will be “Immune control of HIV infection”.

Visit the ECCMID 2020 website to find out about our outstanding keynote speakers!

› Read more

19th ESCMID Summer School – Registrations now open

EITaF Mailing list: Subscribe to receive outbreak news in your inbox!

Did you know that you can now receive email alerts every time that a new piece of EITaF Outbreak News is published – EITaF is the official ESCMID source for news about the coronavirus outbreak.

If you log in to your ESCMID account using your ESCMID login credentials and choose the link ‘Newsletter and Mailing List’ in the right-hand column, You can opt-in to receiving EITaF news alerts.

› Read more

Course announcement: Colistin and other last-line anibiotics against XDR/PDR Gram-negatives – Antwerp, Belgium

Don’t miss the upcoming ESCMID Postgraduate Education course ‘Colistin and other last-line anibiotics against XDR/PDR Gram-negatives’ to be held in Antwerp, Belgium from 1-3 July 2020.

Find out about this and other upcoming ESCMID Educational Courses and Workshops on the ESCMID courses website.

› Read more

ECCMID 2020 Programme Book Grants 2020

Did you know that all money collected from the sale of ECCMID 2020 printed programme books (€20 each during registration) is contributed to supporting abstract authors from low-income countries to attend ECCMID.

Read about the 6 current grantees on the new-look ECCMID Website. More grants will be made available as the remaining programme books are sold.

› Read more

Open call to join the CMI editorial team

Clinical Microbiology and Infection (CMI) is looking for an editor in clinical microbiology to join the editorial team. They are looking for an editor who will deal mainly with studies done in the laboratory, whether the routine clinical laboratory or a research one. CMI aims to aid the readers in using research evidence for the benefit of patients. Improving the methods and the reporting of results is a worthy goal, and you can contribute by being an editor. The call is open until March 31st 2020. Read more about the call and how to apply for this opportunity here.

› Read more

CMI highlight: Semi-mechanistic PK-PD modelling of combined polymyxin B and minocycline against a polymyxin-resistant strain of Acinetobacter baumannii

Acinetobacter baumannii is one of the most difficult to treat multi-drug resistant (MDR) pathogens responsible for opportunistic nosocomial infections worldwide. It can cause a wide range of infections and has the ability to become resistant to broad range of drugs. In face of these resistances, interest in using neglected and disused antibiotics like polymyxins (colistin and polymyxin B (PMB)) has surged, especially in combination with other antibiotics like the carbapenem minocycline (MIN), as the last line of defence against MDR A. baumannii. V. Aranzana-Climent et al. develop a semi-mechanistic PK/PD model to gain insights on the qualitative and quantitative determinants of the interaction between PMB and MIN.

The authors’ model shows that the combination of PMB and MIN could work at clinically achievable concentrations of both antibiotics. Notably, the simulations essentially show the asymmetric nature of the interaction, where MIN is driving the effect and PMB is helping, suggesting that MIN should be used at relatively high dose whereas PMB could be used at relatively low dose. This synergy was observed also in PMB resistant A. baumannii. The authors also conclude that further study of protein binding of MIN in humans is necessary before any definitive recommendation can be issued.

› Read more